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Abstract 
Background: Reliable and comprehensive information on the burden of malaria is critical for guiding national and 
international efforts in malaria control. The purpose of this review is to provide an overview of published data and 
available information on malaria resulting from field studies/investigations conducted in the Republic of Congo (RoC) 
from 1992 to 2015, as baseline for assisting public health authorities and researchers to define future research priori‑
ties as well as interventions.
Methods: This review considers data from peer‑reviewed articles and information from the National Malaria Control 
Programme reports, based on field investigations or samples collected from 1992 to 2015. Peer‑reviewed papers were 
searched throughout online bibliographic databases PubMed, HINARI and Google Scholar using the following terms: 
“malaria”, “Congo”, “Brazzaville”, “prevalence”, “antimalarial”, “efficacy”, “falciparum”, “genetic”, “diversity”. Original articles and 
reviews were included and selection of relevant papers was made.
Results: Twenty‑eight published articles were included in this review and two additional records from the National 
Malaria Control Programme were also considered. The majority of studies were conducted in Brazzaville and 
Pointe‑Noire.
Conclusion: The present systematic review reveals that number of studies have been conducted in the RoC with 
regard to malaria. However, their results cannot formally be generalized at the country level. This suggests a need for 
implementing regular multisite investigations and surveys that may be representative of the country, calling for the 
support and lead of the Ministry of Health.
Keywords: Malaria, Plasmodium falciparum, Review, Health research, Republic of Congo
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Malaria is a life-threatening disease caused by protozoan 
parasites of the genus Plasmodium that are transmitted 
to humans through the bites of infected Anopheles mos-
quitoes. Five different Plasmodium species have been 
demonstrated to infect humans: Plasmodium falcipa-
rum, Plasmodium vivax, Plasmodium ovale, Plasmodium 
malariae and Plasmodium knowlesi. Of these, P. falci-
parum is the most dangerous, with the highest rates of 
complications and mortality [1].
The scaling-up of interventions has reduced the num-
ber of malaria cases and deaths between 2000 and 2015 
[2–4]. In 2000, the World Health Organization (WHO) 
estimated 262 million cases of malaria globally, lead-
ing to 839,000 deaths against 214 million cases and 
438,000 deaths in 2015 [2]. Sub-Saharan Africa remains 
the region with the highest disease burden and accounts 
for 88 and 90% of the global clinical cases and deaths, 
respectively [2].
The Republic of Congo (RoC) is one of the 54 countries 
where malaria transmission is still high [2]. The coun-
try is located in the central-western part of sub-Saharan 
Africa, along the Equator, laying between latitudes 4°N 
and 5°S, and longitude 11° and 19°E (Fig. 1). It occupies a 
total surface of 342,000 km2 with a population estimated 
to be 4,800,000 inhabitants, with 61% of its total popu-
lation living in the two biggest cities, namely Brazzaville 
and Pointe-Noire [5]. Accordingly, the RoC is one of the 
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most urbanized countries in Africa. The capital, Brazza-
ville, is located along the Congo River, in the south of the 
country, immediately across from Kinshasa, the capital 
of the Democratic Republic of Congo. Since the coun-
try is located on the Equator, the climate is consistently 
humid year-round, with the average day temperature of 
25 °C and night between 16 and 21 °C [6]. Two-thirds and 
one-third of the surface area of RoC is covered by for-
ests and savannah, respectively. The average yearly rain-
fall ranges from 1100 mm in the south to over 2000 mm 
in the central and north parts of the country. The rainy 
season which lasts 9  months, has two rainfall maxima: 
one in March–May and another in September–Novem-
ber [6]. The dry season is from June to August. A recent 
entomological survey in RoC jointly conducted by the 
WHO and the Ministry of Health and Population (MHP) 
showed that the transmission dynamic of malaria in the 
country follows two different patterns: (1) a year-round 
perennial transmission in forest areas, with an estimated 
entomological inoculation rate (EIR) of 200–1000 infec-
tive bite/person/year, and (2) a seasonal transmission in 
savanna areas where the high transmission period lasts 
7–10  months and is directly correlated with the rainfall 
and the EIR is estimated to be 80–200 infective bites/
person/year [7]. Despite considerable efforts and pro-
gress in malaria control over the past decades [adoption 
of artemisinin-based combination therapy (ACT) for the 
treatment of uncomplicated malaria in 2006, using either 
artemether–lumefantrine (AL) or artesunate–amodi-
aquine (ASAQ), use of intermittent preventive treatment 
with sulfadoxine-pyrimethamine for pregnant women 
(IPTp-SP), mass distribution of long-lasting insecticide-
treated mosquito nets (LLINs) from 2008 to 2012 and 
free anti-malarial treatment for children aged >15  years 
since 2008], it remains one of the important public health 
problems [8]. All over the country, P. falciparum is the 
predominant malaria parasite and Anopheles gambiae 
the predominant mosquito vector. The latest estimations 
from the National Malaria Control Programme (NMCP) 
indicate that clinical malaria account for 47.9% of all out-
patient consultations in public hospitals, 64.8% of hospi-
tal admissions and 18.4% of deaths [5].
Clearly, the country is still struggling with the con-
trol phase where expensiveness of the control program 
as well as its sustainability, resistance of the parasite to 
anti-malarial drugs and that of vectors to insecticides are 
some of the challenges. However, some research publica-
tions have reported a decrease in clinical malaria prev-
alence in Southern and Northern sentinel sites of the 
country [9, 10].
The purpose of this review was to provide an overview 
of published data and available information from the 
NMCP of the MHP on malaria situation in RoC includ-
ing prevalence/incidence trends, vectors, anti-malarial 
drug efficacy and parasite genetics based on field studies 
conducted from 1992 to 2015. This may assist in defining 
future research and intervention priorities.
Methods
Search strategy
To collect research data on malaria in RoC, peer-
reviewed articles have been retrieved from online 
Fig. 1 Map of the Republic of Congo (RoC) with its 12 departments
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bibliographic databases PubMed, HINARI and Google 
scholar using the following keywords: “malaria”, “Congo”, 
“Brazzaville”, “1992”, “prevalence”, “antimalarial”, “effi-
cacy”, “falciparum”, “genetic”, “diversity”, “resistance”, 
“markers”. Reference lists of selected papers were used as 
leads for identification of additional studies. The Boolean 
operators “AND”, “OR” and “>” were used to combine two 
or three terms. In addition, reports from the NMCP were 
reviewed at the NMCP headquarters in Brazzaville. Pre-
defined medical subject heading (MeSH) was not used to 
avoid restricting searches.
Study/document selection and data consideration
Studies were included in the review if they explicitly 
reported on one of the considered aspect of malaria in 
RoC with: (1) samples collected in the country, (2) a clear 
description of the methods section (providing the follow-
ing information: study area, period of sample collection, 
type of samples collected and study population) and (3) 
no review articles. An overall of 33 studies were retrieved 
from the search of peer-reviewed papers, of which five 
were excluded because of duplications (similar analy-
sis on same samples or study population) or they were 
review articles. Therefore, 28 studies including full text 
articles, and short reports written in English or in French 
were selected and reviewed. Two additional documents 
from the NMCP were considered (Fig. 2).
Results
Malaria parasite prevalence
Published articles included in this review were of sam-
ples collected from 1992 to 2015 (Table 1). Of these, nine 
articles were identified with information on the incidence 
or the prevalence of malaria parasite infection (Table 2) 
[9, 11–18]. Most of these studies were performed in 
children aged ≤15  years. Investigations were conducted 
in different areas of the country, with most of them being 
located in Brazzaville and mainly reported the presence 
of one malaria species, namely P. falciparum. There was 
only one study in which three plasmodial species were 
detected with a predominance of P. falciparum over P. 
malariae (2.9%) and P. ovale (0.7%) [11]. Six of the P. ovale 
isolates (two isolates from Brazzaville, two from Pointe-
Noire and two from Gamboma) were further character-
ized by Oguiket et  al. using conventional and real-time 
quantitative PCR methods to discriminate P. ovale curtisi 
and P. ovale wallikeri. The two isolates from Brazzaville 
were identified as P. ovale curtisi, while the remaining 
four isolates were identified as P. ovale wallikeri [19]. In 
another study, a focus was put on providing evidence of 
transmission of P. vivax in RoC [12]. The authors found 
that 13% of samples, collected in 2007 in Pointe-Noire 
and tested by enzyme-linked immunosorbent assay, had 
antibodies to P. vivax-specific antigens. Accordingly, they 
concluded that in conjunction with the frequent reports 
of travellers returning from western and central Africa 
with diagnosed P. vivax infections, their findings make an 
argument for the presence and continued transmission of 
P. vivax in RoC. How and where precisely is still unclear 
and deserves to be further investigated.
The study with the largest sample size was conducted 
from 2003 to 2006 in southern part of Brazzaville just 
before introduction of ACT in the country [13]. The 
authors found that in peri-urban area, of more than 1090 
febrile patients examined, 44.7% had clinical malaria. 
Whereas in urban area, of 10,603 febrile patients exam-
ined, only 23.8% had clinical malaria. It was also observed 
that the pick of infections occurred between November 
and January and in March-April [13]. In the study con-
ducted by Tsumori et  al. [11] with samples collected in 
2005–2006 from patients residing in urban and peri-
urban areas of Brazzaville, Pointe Noire and Gamboma, 
plasmodial infection was screened by microscopy and by 
PCR. By microscopy, 37% of patients residing in urban 
areas were positive for P. falciparum compared to 59% 
of those residing in the peri-urban areas. With regard to 
PCR corrected results, the percentages rose to 42% P. fal-
ciparum positive for the urban residents and 75% posi-
tive for peri-urban residents, indicative a percentage of 
11 and 20% of submicroscopic infections in these two 
populations, respectively. Another important study con-
ducted before adoption of ACT was concomitantly done 
in different pediatric services of four hospitals in Brazza-
ville from January to August 2006 [14]. With the objec-
tive of assessing the real prevalence of severe malaria 
among young children in pediatric services, this study 
included more than 10,000 children. The overall severe 
malaria prevalence was 14.7%. Children of >5  years old 
Articles identified trough 
online database search
(n = 33)
Additional records from the National 









Fig. 2 Summary of the search strategy
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Table 1 Summary of published articles included in the review
References Period of sample collection Year of publication Study area Age of participants
Chandenier et al. [20] 1993 1995 Brazzaville, Niari, Kouilou, Pool 6–10 years
Durand et al. [21] 1998 2003 Pointe‑Noire No limit
Nsimba et al. [22] 1999–2002 2004 Brazzaville, Pointe‑Noire 0.5–<5 years
Nsimba et al. [23] 1999–2002 2005 Brazzaville, Pointe‑Noire 0.5–<5 years
Mayengue et al. [24] 2003 2005 Brazzaville ≤5 years
Ndounga et al. [25] 2003–2004 2007 Brazzaville <5 years
Ndounga et al. [13] 2003–2006 2008 Brazzaville No limit
Van den Broek et al. [26] 2004 2006 Kindamba 0.5–<5 years
Mayengue et al. [27] 2005 2011 Brazzaville No limit
Ndounga et al. [28] 2005 2013 Brazzaville No limit
Pradine et al. [29] 2005–2006 2006 Pointe‑Noire 1.4–17 years
Tsumori et al. [11] 2005–2006 2011 Brazzaville, Gamboma, Pointe‑Noire No limit
Oguike et al. [19] 2005–2006 2011 Brazzaville, Gamboma, Pointe‑Noire No limit
Moyen et al. [14] 2006 2010 Brazzaville ≤15 years
Ndounga et al. [30] 2006 2012 Brazzaville 0.5–10 years
Murai et al. [31] 2006 2015 Brazzaville, Gamboma, Pointe‑Noire No limit
Mita et al. [32] 2006 2016 Brazzaville, Gamboma, Pointe‑Noire No limit
Culleton et al. [12] 2007 2009 Pointe‑Noire No limit
Koekemoer et al. [33] 2009 2011 Boutoto Not applicable
Koukouikila‑Koussounda et al. [15] 2010 2012 Brazzaville <10 years
Ibara‑Okabande et al. [34] 2010–2011 2012 Brazzaville <10 years
Ndounga et al. [35] 2010–2011 2015 Brazzaville <10 years
Ossou‑Nguiet et al. [18] 2011 2013 Brazzaville 0.4–14 years
Mbongo et al. [17] 2011–2013 2015 Brazzaville 15–39 years
Ntoumi et al. [9] 2011–2012 2013 Brazzaville, Pointe‑Noire ≤15 years
Koukouikila‑Koussounda et al. [36] 2012–2013 2015 Brazzaville 12–44 years
 Ntoumi et al. [16] 2012–2013 2016 Brazzaville 12–44 years
Singana et al. [10] 2012–2013 2016 Owando <12 years
Table 2 Main findings of studies that assessed the prevalence of malaria parasite infection
a Prevalence in sub‑urban area
b Prevalence in urban areas
c Children
d Pregnant women
e No age limit




Asymptomatic infection Infection in febrile patients Severe malaria
Microscopy (%) PCR (%) Microscopy (%) PCR (%) Microscopy (%)
Ndounga et al. [13] 2003–2006 2008 – – 23.8b,e versus 44.7a,e – –
Tsumori et al. [11] 2005–2006 2011 – – 37b,e versus 59a,e 42b,e versus 75a,e –
Moyen et al. [14] 2006 2010 – – – – 14.7b
Koukouikila‑Kous‑
sounda et al. [15]
2010 2012 8.6a,c 16a,c – – –
Ossou‑Nguiet et al. 
[18]
2011 2013 – – – 34.9b
Mbongo et al. [17] 2011–2013 2015 4.4b,d – – – –
Ntoumi et al. [9] 2011–2012 2013 – – 12b,c versus 17b,d – –
Ntoumi et al. [16] 2012–2013 2016 7a,d 19a,d – – –
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were the most affected group as the rate reached 57.6%. 
The authors also determined 26.3% of death rate in this 
children population [14].
Following the replacement of chloroquine with ASAQ 
or AL in 2006 for the treatment of uncomplicated 
malaria, the first study that reported the prevalence of 
malaria parasite infection was conducted in 2010 in a 
peri-urban area of southern Brazzaville [15], an area 
which has been characterized as highly endemic with per-
ennial malaria transmission [37]. In this study, from April 
to June 2010, 313 children below 10 years of age enrolled 
in a cohort for malaria surveillance were screened for 
P. falciparum asymptomatic carriage using microscopy 
and PCR as diagnostic techniques. The reported preva-
lence of infection was 8.6 and 16% by microscopy and 
PCR, respectively [15]. In a prospective and longitudinal 
study conducted from January 2011 to December 2013 at 
University Hospital Centre of Brazzaville, 13,883 preg-
nant women were screened by microscopy at delivery 
for malaria parasite carriage and newborns from positive 
mothers were further screened. A total of 610 mothers 
(4.4%) were found positive and 64% of newborns from 
these mothers also carried malaria parasites [17]. From 
October 2011 to February 2012, Ntoumi et  al. carried 
out a malaria survey among under 15 years old children 
and pregnant women in different public health centers in 
Brazzaville and Pointe-Noire [9]. The main objective of 
the study was to document laboratory-confirmed cases 
of malaria using microscopy and/or rapid diagnostic 
tests (RDTs). P. falciparum was the only species detected 
and the prevalence of infections among more than 3000 
children and 700 pregnant women ranged from 8 to 29, 
and 8 to 24%, respectively [9]. Another study by Ntoumi 
et  al. using blood samples collected from March 2012 
to December 2013 in an antenatal clinic located in peri-
urban area of southern Brazzaville among pregnant 
women, reported a prevalence of asymptomatic P. fal-
ciparum infection at 7 and 19% when using microscopy 
and PCR, respectively [16]. A study by Ossou-Nguiet 
et al. conducted from July to December 2011 at the inten-
sive care department of pediatric service of the University 
Hospital Center focused on determining the frequency 
and determinants of severe malaria among hospitalized 
children. A total of 1135 children were enrolled in this 
study and 34.9% (396) of them were diagnosed as severe 
malaria cases. Among them, 35.9% were further classified 
as coma cases, while 23.5, 20.8, 10.3, 7.4 and 3.6% were 
found to experience convulsions, coma and anaemia, 
prostration, convulsions and anaemia, and convulsions 
and respiratory distress, respectively [18].
Apart from the published articles, data available at the 
Ministry of Public Health and provided by the NMCP 
were also considered. In the national malaria report 2015 
(released in 2016) [8] and the strategic plan for malaria 
control in the RoC from 2014 to 2018 (released in 2014) 
[5], the number of confirmed malaria cases recorded in 
public health centres countrywide from 2008 to 2015 
were reported. Overall, malaria showed a fluctuation 
trend during the last 8  years (Fig.  3). The number of 
cases was 160,000 in 2008, 150,000 in 2009, 260,000 in 
2010, 277,263 in 2011, 117,640 in 2012, 182,026 in 2013, 
248,159 in 2014 and 198,047 in 2015 [5, 8]. As there is no 
such data for the years before ACT, it is difficult to give a 
comprehensive interpretation of this fluctuation.
Malaria vectors
Malaria entomological studies are very limited in the 
RoC. From 1992 to June 2016, only one published inves-
tigation was found [33]. Conducted in 2009 in the vil-
lage Boutoto located in the vicinities of Pointe-Noire, the 
study aimed to obtain the baseline vector information. 
Anopheles gambiae sensu stricto (s.s.) was the only mos-
quito species identified, and it had a high P. falciparum 
infection rate (9.6%). In this study, insecticide suscepti-
bility was also assessed and the authors mentioned that 
multiple insecticide resistance was detected in this vector 
population with full susceptibility observed to only one 
insecticide class, the organophosphate [33].
In 2014, the NMCP documented entomological sur-
veys conducted in 2013 by Antonio-Nkondjio and Bit-
sindu in the Bouenza department located at 300  km 
southern Brazzaville. Anopheles gambiae s.l. and Anoph-
eles funestus were reported as the predominant vectors, 
while other species including Anopheles coustani, Anoph-
eles hancocki, Anopheles nili, Anopheles moucheti and 
Anopheles paludis were found to be potential secondary 
vectors [5].
Fig. 3 Number of malaria cases as reported by the National Malaria 
Control Program
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Genetic diversity and multiplicity of Plasmodium 
falciparum in isolates from RoC
Number of information on the genetic diversity and the 
multiplicity of P. falciparum infections have been gener-
ated using samples from the RoC. A total of 8 published 
articles have been found, for which, different molecular 
markers have been used. The genes for the merozoite sur-
face protein 1 and 2 have been used, msp2 alone has been 
used in four investigations [9, 15, 16, 34], msp1 and msp2 
in one study [27], and microsatellites in two studies with 
one utilizing msp1 in addition to the microsatellite mark-
ers [11, 21].
In 2003, analysing 32 isolates of P. falciparum collected 
in 1998 at Pointe Noire, Durand et  al. reported a high 
genetic diversity based on 28 microsatellites with a mean 
number of alleles per locus of 7.75 and the expected het-
erozygosity of 0.78 [21]. This trend was further confirmed 
by Tsoumori et al. who analysed microsatellite loci of P. 
falciparum isolates collected in urban and peri-urban 
areas in southern Brazzaville in 2005 [11]. In the study by 
Mayengue et al. [27], with 125 P. falciparum clinical iso-
lates collected from children in south part of Brazzaville 
in 2005, the allelic specific msp1 and msp2 genotyping 
showed that malaria parasite population in Brazzaville 
is highly diverse. A total of 15 msp1 and 20 msp2 dis-
tinct alleles were identified. For msp1, K1 was found to 
be the predominant allelic type, whereas 3D7 family was 
the most prevalent for msp2. The overall mean MOI was 
2.2 and 72% of the isolates carried more than one geno-
type [27]. In 2010, Four years after adoption of ACT in 
the country, Koukouikila-Koussounda et al. characterized 
the genetic polymorphism of msp2 gene in P. falciparum 
isolates collected from Congolese children with asymp-
tomatic infections [15]. Eighten different allele types 
were identified, suggestive of a high genetic diversity, in 
which, 8 belonged to the 3D7 family, which was found 
to be the predominant family, and 10 to FC27. However, 
the MOI and the rate of isolates with multiple genotypes 
were found to be low, 1.3 and 28%, respectively [15]. The 
cohort of children enrolled in this study was followed up 
for a year to monitor uncomplicated falciparum malaria 
episodes and isolates collected from some of the chil-
dren who experienced uncomplicated malaria were later 
on analysed by Ibara-Okabando et al. [34] with regard to 
parasite diversity using msp2 as molecular marker. A high 
genetic diversity of parasite population was observed 
with 21 different alleles detected (11 for 3D7 family and 
10 for the FC27). Here, the MOI of 1.7 was determined 
and 54% the isolates harboured more than one msp2 gen-
otype [34].
Recent studies among children and pregnant women 
from Brazzaville and Pointe-Noire conducted in 2011–
2012 by Ntoumi et al. [9] provided additional information 
on the genetic diversity and the MOI. The molecular 
characterization of the msp2 gene revealed the presence 
of 11 (5 of 3D7 and 6 of FC27) and 22 alleles (13 of 3D7 
and 9 of FC27) in P. falciparum isolates collected from 
2011 to 2012 from children aged >15 years with uncom-
plicated malaria in Brazzaville and Pointe-Noire, respec-
tively. The MOI was similar (about 1.7) in the two cities 
[9]. In another study, analysing isolates collected in 2012–
2013 from pregnant women with asymptomatic P. fal-
ciparum infection using the same molecular marker, 11 
alleles of the 3D7 family and 18 of the FC27 family were 
detected [16]. This is indicative of a higher genetic diver-
sity in isolates from pregnant women that that of chil-
dren. The rate of alleles belonging to the 3D7 and FC27 
families was 62 and 38%, respectively. The authors also 
reported that 40.3% of the isolates harboured more than 
one msp2 genotype and the overall MOI was 1.6 [16].
Drug efficacy studies
In the period 1992 to 2005, before adoption of ACTs, six 
efficacy in  vivo studies had been conducted, of which 
one was based on the 1973 WHO protocol for asympto-
matic children to assess chloroquine efficacy [20], one on 
14-day follow-up WHO protocol to assess chloroquine 
and sulfadoxine-pyrimethamine (SP) [22], and four on 
the current 28-day follow-up WHO protocol to evaluate 
therapeutic efficacy of chloroquine [24], SP [25], ASAQ, 
AL and AS + SP [26], AL and then ASAQ [28, 30]. The 
study based on the 1973 WHO protocol was conducted 
in 1993 in three southern regions of the country (Niari, 
Kouilou and Pool which included Brazzaville) and the 
authors reported that 7  days after the standard three-
day treatment with chloroquine at 25  mg/kg, 20–60% 
of cases were still found to carry malaria parasites [20]. 
In the study using the 14-day follow-up WHO proto-
col and conducted in Brazzaville and Pointe-Noire from 
1999 to 2002, the cure rate of chloroquine was 38.5% and 
that of SP was 95.8%. SP efficacy was further assessed in 
the second phase of this study and the cure rate of 100% 
was recorded [22]. However, studies carried out using 
the 28-day follow-up WHO protocol showed high level 
of treatment failure for chloroquine (95.7%) [24] and 
SP (31.2%) [25], while AL and ASAQ were found to be 
highly effective to treat uncomplicated malaria with the 
reported 28-day PCR-corrected cure rates of 96.9 [30] 
and 100% [26] for AL, and 94.4% [28] and 98.5% [26] for 
ASAQ. AS + SP, with the 28-day PCR-corrected cure rate 
of 90% was also effective but less than AL and ASAQ [26].
In 2006, the government of the RoC adopted a new 
treatment policy for uncomplicated malaria with ASAQ 
and AL as the first and second-line drugs, respectively 
[38]. However, in 2014, AL became the first- and ASAQ 
the second-line drug. Since 2006, two studies were 
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conducted, one in Brazzaville and the other in Owando 
(located at 550  km to north of Brazzaville), to evalu-
ate the efficacy of ASAQ and AL. The study in Brazza-
ville reported a PCR-corrected efficacy of 97% for ASAQ 
and 96.4% for AL [35]. In the study in Owando et al., the 
PCR-corrected efficacy was 100% for ASAQ and 98% for 
AL [10].
Plasmodium falciparum in vitro resistance studies
Two studies have been conducted to assess the level of 
in vitro resistance of P. falciparum parasites to standard 
anti-malarial drugs. The isotopic test was used in the 
two studies. The first study was conducted in Brazzaville 
in 1993 and 34 P. falciparum isolates were tested with 
chloroquine, quinine and mefloquine. In addition, halo-
fantrine was also tested on 35 P. falciparum isolates. The 
resistance rates were 61.8, 17.7, 3 and 0% for chloroquine, 
quinine, mefloquine and halofantrine, respectively [20]. 
The second investigation was done in Pointe-Noire where 
P. falciparum isolates were collected from March 2005 
to January 2006 and their sensitivity assessed against 11 
drugs: chloroquine, quinine, mefloquine, atovaquone, 
dihydroartemisinin, doxycycline, cycloguanil, lume-
fantrine, monodesethylamodiaquine, halofantrine and 
pyrimethamine [29]. The in  vitro resistance rates were 
75.5% for chloroquine, 68% for pyrimethamine, 36% for 
cycloguanil, 7% for mefloquine, 6% for quinine, 2% for 
monodesethylamodiaquine and 0% for the remaining 
drugs [29]. These studies contributed demonstrate evi-
dence of high level of chloroquine resistance in the RoC. 
Since adoption of ACT in 2006, no in  vitro study has 
been conducted on field isolates.
Plasmodium falciparum drug resistance genes
A total of eight articles have been found reporting data 
on molecular markers of P. falciparum resistance to anti-
malarials with samples collected from 1999 to 2015 [11, 
15, 23–25, 31, 32, 36]. Overall, six molecular markers 
have been studied: the P. falciparum chloroquine resist-
ance transporter (pfcrt) gene, associated with chloro-
quine resistance, the dihydrofolate reductase (dhfr) and 
the dihydropteroate synthase (dhps) genes, which are 
linked with pyrimethamine resistance and sulfadoxine 
resistance, respectively, the P. falciparum Klech-13 (K13) 
propeller gene, which has recently been linked with arte-
misinin resistance, and MAL10-688956 and MAL13-
1718319 single nucleotide polymorphisms (SNPs) which 
have also recently been proposed as molecular markers 
of artemisinin resistance which is defined as a delayed 
clearance of P. falciparum parasites following ACT. The 
most analysed molecular markers are pfcrt, dhfr and 
dhps for which the main findings are summarized in 
Table 3.
The pfcrt gene has been studied in four articles and for 
all the K76T mutation was characterized. Nsimba et  al. 
[23] with isolates collected in 1999 at Pointe-Noire and in 
2001–2002 at Brazzaville reported a prevalence of 97.1% 
of P. falciparum isolates carrying the 76T mutation. This 
prevalence was similar to the rate of 98% reported by 
Mayengue et al. [24], 88–97% by Tsumori et al. [11], and 
92% by Koukouikila-Koussounda et al. [15].
Molecular analysis of mutations associated with resist-
ance to antifolates was performed by Nsimba et al. [23], 
Ndounga et al. [25], Koukouikila-Koussounda et al. [36], 
and Tsumori et al. [11] (who only analysed the dhfr point 
mutations). In all of these studies, dhfr point mutations 
at codons 51, 59 and 108 were found at high frequen-
cies while the mutation at codon 164 was absent. For 
dhps, high prevalence of the mutation at codon 437 was 
observed in the three studies, while higher frequency of 
the mutation at codon 436 and the presence of mutation 
at codon 540 were only observed in the recent study, with 
samples collected from pregnant women in 2012–2013 at 
Brazzaville [36].
The K13 propeller gene was characterized by Mita et al. 
[32], and MAL10-688956 and MAL13-1718319 SNPs 
have been characterized by Murai et  al. [31]. In both 
studies they used the same set of archived P. falciparum 
isolates collected in 2005–2006 in Brazzaville, Pointe-
Noire and Gamboma, and none of the mutations associ-
ated with artemisinin resistance was found.
Discussion
The purpose of this review is to provide an overview of 
published data and available information on malaria 
situation in RoC and to identify gaps in knowledge in 
order to contribute in research-based solutions adapted 
for the country. In the present review, as the first goal, 
we attempted to determine if there was any change in 
malaria epidemiology in RoC from 1992 to 2015, with 
regard to malaria parasites and vectors and in the pres-
entation of the disease as well. The year 1992 was cho-
sen because the first national policy for malaria control 
established by the NMCP was adopted that year. Besides, 
all the research institutions including those involved in 
malaria research were nationalized.
As a summary, during almost 24  years, a total of 28 
studies published in peer reviewed journals were con-
ducted the RoC in relation to different aspects of malaria 
infection. Concerning malaria burden, lower rates of 
malaria parasite infection in children and adults were 
observed in studies conducted from 2009 to 2015 com-
pared to those conducted from 1992 to 2006 regardless 
of the diagnostic method (microscopy or PCR). This is 
suggestive of a decline malaria prevalence and incidence 
during the past 7 years and might be attributable to the 
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scaling-up of malaria interventions in the country with 
the support of Global fund for HIV/AIDS, malaria and 
tuberculosis, including the use ACT which are freely pro-
vided to children of ≤15 years in public health facilities 
since 2008 associated with mass distribution of LLINs 
from 2008 to 2012. Further evidence on sustainability of 
the trend to the years later is important to ascertain such 
attributes.
With regard to Plasmodium species distribution, P. 
falciparum is by far the predominant malaria parasite 
occurring in the country accounting for almost 100% of 
malaria cases [11]. This observation on the extreme pre-
dominance of P. falciparum in the RoC is in accordance 
with findings from studies conducted in other Central 
African countries [39, 40].
The genetic diversity of P. falciparum was character-
ized trough different studies and the MOI was also deter-
mined. These two parameters are known to be good 
indicators of the level of premunition of populations liv-
ing in endemic areas and correlate with the extent of the 
parasite population diversity as well as the transmission 
intensity [41, 42]. They are also important determinants 
of malaria control interventions. Overall, a significant 
diversity of P. falciparum population has been observed 
in all the studies and this is representative of areas with 
holo- or hyper-endemic malaria transmission. The High 
genetic diversity remains similar before and after intro-
duction of ACT in 2006 and scaling up of control meas-
ures in the RoC. This implies that most of the parasite 
clones are still persisting and the interventions did not 
have impact on specific P. falciparum clones. Lower val-
ues of the MOI (1.3–1.7) have been obtained in stud-
ies conducted after these interventions than those 
conducted before (2.2–2.3). This trend, in addition to low 
rates of parasite carriage observed in studies conducted 
after 2006 may suggest that the implemented control 
measures have resulted in a substantial decrease of trans-
mission. However, this needs to be assessed by conduct-
ing entomological studies that allow determination of the 
EIR in each area, which correlate well with the level of 
malaria transmission.
Vector control is one of the main interventions for an 
effective malaria control programme. To be successful, 
this intervention needs to rely on availability of data on 
vector population, level of transmission and insecticide 
resistance. Unfortunately, only one publication was found 
[33] and this reflects a major gap in knowledge about the 
malaria situation in RoC. In that study, 523 An. gambiae 
complex specimens were collected and the specimen 
identification revealed that all were An. gambiae s.s., of 
which, 95.4% were further molecularly characterized 
as the S-form. Importantly, these vectors were found to 
be highly resistant to multiple insecticide classes. This 
review would classify entomological research as a key 
priority in the country. Moreove, as An. funestus, An. 
coustani and An.hancocki were found to be potential 
minor malaria vectors [5], their implication in malaria 
transmission and the level of resistance to insecticides 
have yet to be further elucidated.
Since the utilization of ACT for the treatment of 
uncomplicated malaria, monitoring studies are required 
to detect any emergence of artemisinin resistant strains 
as it has been already reported from South East Asia 
[43, 44]. Overall in vivo efficacy studies conducted so far 
provided evidence of good efficacy of currently recom-
mended ACT in RoC. It is observed that only one study 
analysed mutations on P. falciparum K13 propeller gene 
in isolates from RoC [32], and it would be important that 
local scientists screen regularly isolates from different 
parts of the country. Chloroquine and SP were banned 
for the treatment of uncomplicated malaria in the RoC 
since 2006 due to high level of parasite resistance. Stud-
ies conducted five to seven years after their withdrawal 
still show high rates of parasites carrying mutations 
associated with resistance to these two molecules. This 
would like to suggest that these molecules remain inac-
tive, despite the fact that SP is still used as intermittent 
preventive treatment in pregnant women. Moreover, 
the presence of the 540 dhps mutation (in P. falciparum 
isolates collected in 2011–2012) [36], which was absent 
before SP withdrawal [23], and higher level of quintuple 
dhfr/dhps mutations might suggest that SP resistance 
become more pronounced.
As a second key priority highlighted by this review is 
the limited number of publications on malaria in preg-
nancy in RoC. For instance, there is no data on malaria 
parasites collected from pregnant women before the 
introduction of ACT and the first data were published 
in 2013 [9]. The researchers from Congo working on 
malaria are also involved in the Central Africa Network 
on Tuberculosis, HIV/AIDS and Malaria (CANTAM) 
which aims at building capacities for the conduct of clini-
cal trials. Therefore, it would be of interest to test alter-
native drugs for preventing malaria during pregnancy in 
Congolese women.
Conclusion
A total of 28 peer reviewed articles and two official docu-
ments from the NMCP were included in this review and 
have shown that malaria is still endemic in the country. 
Unfortunately, the majority of studies were conducted in 
Brazzaville followed by Pointe-Noire (the two main cit-
ies). Therefore, results cannot formally be generalized. 
We note two major positive points: ASAQ and AL are 
highly efficacious in treatment of uncomplicated malaria 
and there is substantial reduction of malaria transmission 
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since introduction of ACTs in the country. However, a 
strong resistance to SP is observed in parasites collected 
from Congolese pregnant women.
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